Jason Faris

Suggest Changes
  • Citations Per Year
Learn More
Background This phase II open-label, multicenter study evaluated the efficacy, safety, and tolerability of TAK-264 in previously treated patients with advanced or metastatic pancreatic adenocarcinoma(More)
  • 1